Hims & Hers on Saturday said it would stop offering its copycat Wegovy weight-loss pill. The decision comes after Novo Nordisk, maker of Wegovy, and the U.S. Food and Drug Administration threatened ...

The FDA announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded semaglutide (Wegovy) weight-loss ...

Hims & Hers Health (HIMS) fell ~8% in the premarket on Friday after FDA Commissioner Marty Makary said that his agency will take swift action against “companies mass-marketing illegal copycat drugs.” ...

I’m thrilled to launch my own coffee, the Seen Through Glass blend, created with Per’La Specialty Roasters in the UK. With flavour profiles of caramel, dark chocolate, and orange, this custom coffee ...

FDA leadership indicated planned swift enforcement against companies mass-marketing non-approved “copycat” drugs, underscoring inability to verify safety, quality, or effectiveness outside the ...

Feb 5 (Reuters) - The U.S. Food and Drug Administration (FDA) will take swift action against companies that mass-market "illegal copycat drugs" by claiming they are similar to FDA-approved products, ...

Feb. 9 (UPI) --Novo Nordisk, the maker of the weight loss drug Wegovy, is suing Hims & Hers for selling a cheaper version of the drug, the company announced Monday. Novo Nordisk claims that Hims & ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. The US drug regulator plans to crack down on copycat versions of popular weight-loss drugs sold by Hims & ...

Add Yahoo as a preferred source to see more of our stories on Google. U.S. Food and Drug Administration Commissioner Marty Makary speaks during a press conference at the Department of Health and Human ...

Investing.com -- Hims & Hers Health (NYSE:HIMS) stock fell 10% Friday after the FDA warned it would take action against companies marketing unauthorized versions of approved medications, a day after ...